A class action lawsuit has been filed against Chemours Company and some of its officers for allegedly overstating demand for their Opteon products and providing misleading financial guidance during the period from February to August 2026. The lawsuit claims Chemours failed to disclose that demand was actually decreasing due to overselling in the previous year, which made their public statements false and misleading. Investors who purchased Chemours securities during this time are encouraged to join the case, with a deadline to request lead plaintiff status by December 7, 2026. The law firm Bronstein, Gewirtz & Grossman is representing investors on a contingency fee basis, meaning no upfront cost for investors.
The class action lawsuit involving Chemours Company provides context for market activity in the Basic Materials sector. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 12, 2026 00:11 WIB: out of 62 priced US stocks, 40 rose and 20 fell today. Notable movers include GGB at USD 5.12 with a 1-day change of +4.07%, CTVA at USD 13.22 with a 1-day change of -3.82% and 100% buy order activity, and AU at USD 94.16 with a 1-day change of +3.72% and 100% buy order activity.
Acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), was linked to an 18% lower risk of death, hospitalization, and disease progression compared to tafamidis in a large U.S. electronic health record study of 2,684 patients. The stud...
Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...
The European Union is consulting on whether developers of noncustodial Bitcoin wallets should require certification before releasing their software publicly. This review is part of a broader assessment of the EU's Markets in Crypto-Assets Regulation ...
BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...
